Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 118

    1.

    Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.

    Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC.

    J Ovarian Res. 2010 Apr 29;3:11.

    PMID:
    20429876
    [PubMed]
    Free PMC Article
    2.

    Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.

    Yallapu MM, Gupta BK, Jaggi M, Chauhan SC.

    J Colloid Interface Sci. 2010 Nov 1;351(1):19-29. Epub 2010 May 12.

    PMID:
    20627257
    [PubMed - indexed for MEDLINE]
    3.

    Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer.

    Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC.

    Curr Drug Metab. 2011 Sep 5. [Epub ahead of print]

    PMID:
    21892919
    [PubMed - as supplied by publisher]
    4.

    Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.

    Misra R, Sahoo SK.

    Mol Pharm. 2011 Jun 6;8(3):852-66. Epub 2011 Apr 15.

    PMID:
    21480667
    [PubMed - indexed for MEDLINE]
    5.

    Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.

    Wahl H, Tan L, Griffith K, Choi M, Liu JR.

    Gynecol Oncol. 2007 Apr;105(1):104-12. Epub 2006 Dec 15.

    PMID:
    17174384
    [PubMed - indexed for MEDLINE]
    7.

    HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

    Cancer Biol Ther. 2011 Nov 1;12(9):837-45. Epub 2011 Nov 1.

    PMID:
    21885917
    [PubMed - in process]
    8.

    [Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line].

    Yang XK, Zheng F, Chen JH, Gao QL, Lu YP, Wang SX, Wang CY, Ma D.

    Ai Zheng. 2002 Dec;21(12):1288-91. Chinese.

    PMID:
    12520732
    [PubMed - indexed for MEDLINE]
    9.

    BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.

    Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C, Wei Y.

    PLoS One. 2011;6(5):e20586. Epub 2011 May 31.

    PMID:
    21655183
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

    Montopoli M, Ragazzi E, Froldi G, Caparrotta L.

    Cell Prolif. 2009 Apr;42(2):195-206. Epub 2009 Feb 18.

    PMID:
    19236381
    [PubMed - indexed for MEDLINE]
    11.

    Final Report on Carcinogens Background Document for Formaldehyde.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

    PMID:
    20737003
    [PubMed - as supplied by publisher]
    12.

    Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780.

    Zheng LD, Tong QS, Wu CH.

    Chin J Integr Med. 2006 Jun;12(2):126-31.

    PMID:
    16800992
    [PubMed - indexed for MEDLINE]
    13.

    Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.

    Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW.

    Mol Carcinog. 2010 Jan;49(1):13-24.

    PMID:
    19676105
    [PubMed - indexed for MEDLINE]
    14.

    Final Report on Carcinogens Background Document for Styrene.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.

    PMID:
    20737009
    [PubMed - as supplied by publisher]
    15.

    Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.

    Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P.

    Cancer Biol Ther. 2007 Feb;6(2):178-84. Epub 2007 Feb 5.

    PMID:
    17218783
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling.

    Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R.

    Chem Biol Interact. 2009 Oct 7;181(2):263-71. Epub 2009 Jun 30.

    PMID:
    19573523
    [PubMed - indexed for MEDLINE]
    17.

    Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.

    Henkels KM, Turchi JJ.

    Cancer Res. 1999 Jul 1;59(13):3077-83. Erratum in: Cancer Res 2000 Feb 15;60(4):1150.

    PMID:
    10397248
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy.

    Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A.

    J Nanobiotechnology. 2007 Apr 17;5:3.

    PMID:
    17439648
    [PubMed]
    Free PMC Article
    19.

    Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.

    Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K.

    Gynecol Oncol. 2003 Apr;89(1):37-47.

    PMID:
    12694652
    [PubMed - indexed for MEDLINE]
    20.

    Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells.

    Saydmohammed M, Joseph D, Syed V.

    J Cell Biochem. 2010 May 15;110(2):447-56.

    PMID:
    20235152
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk